Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction

Oncogene. 2011 Mar 31;30(13):1551-65. doi: 10.1038/onc.2010.539. Epub 2010 Dec 20.

Abstract

Release from growth factor dependence and acquisition of signalling pathway addiction are critical steps in oncogenesis. To identify genes required on mammalian target of rapamycin (mTOR) addiction, we performed a genome-wide short hairpin RNA screen on a v-H-ras-transformed Pten-deficient cell line that displayed two alternative growth modes, interleukin (IL)-3-independent/mTOR-addicted proliferation (transformed growth mode) and IL-3-dependent/mTOR-non-addicted proliferation (normal growth mode). We screened for genes required only in the absence of IL-3 and thus specifically for the transformed growth mode. The top 800 hits from this conditional lethal screen were analyzed in silico and 235 hits were subsequently rescreened in two additional Pten-deficient cell lines to generate a core set of 47 genes. Hits included genes encoding mTOR and the mTOR complex 2 (mTORC2) component rictor and several genes encoding mitochondrial functions including components of the respiratory chain, adenosine triphosphate synthase, the mitochondrial ribosome and mitochondrial fission factor. Small interfering RNA knockdown against a sizeable fraction of these genes triggered apoptosis in human cancer cell lines but not in normal fibroblasts. We conclude that mTORC2-addicted cells require mitochondrial functions that may be novel drug targets in human cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / biosynthesis
  • Animals
  • Cell Line, Tumor
  • Cell Proliferation
  • Glucose / metabolism
  • Humans
  • Interleukin-3 / pharmacology
  • Mice
  • Mitochondria / physiology*
  • RNA Interference*
  • RNA, Small Interfering / genetics*
  • Signal Transduction
  • TOR Serine-Threonine Kinases / physiology*
  • Trans-Activators / physiology*

Substances

  • Interleukin-3
  • RNA, Small Interfering
  • Trans-Activators
  • Adenosine Triphosphate
  • TOR Serine-Threonine Kinases
  • Glucose